
Conference Coverage
4 days ago
What Does Minimal Residual Disease Mean?Latest Content

Cancer in the Rearview Mirror

Facing Lung Cancer Together: A Patient and Care Partner Share Their Journey

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

Accepting That You Are Changed by Cancer

FDA Grants Breakthrough Designation to INCA-33989 in Essential Thrombocythemia

Shorts







Podcasts
Videos
All News

Six-year phase 3 follow-up showed adding Loqtorzi to chemotherapy nearly doubled survival for recurrent or metastatic nasopharyngeal cancer.

As I reflect on my lung cancer journey, I look back to the 2018 holiday season, feeling comfortable and at peace.

I attended this year’s Light the Night walk in remembrance of my sister, reflecting on her 11-year battle and enduring identity as a cancer survivor.

Newly diagnosed with stage 3 prostate adenocarcinoma? Understand your diagnosis and explore multimodality treatment options for an informed cancer journey.

This guide features information from diagnosis to treatment of adenocarcinoma of the bladder.

Asian women who do not smoke in Northern California face rising lung cancer rates which are often diagnosed late due to current screening gaps.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

The FDA granted review to a supplemental biologics license application for Opdivo plus chemo for previously untreated stage 3/4 classical Hodgkin lymphoma.

I struggle to understand why people support policies and leaders that make healthcare less affordable and accessible for everyone.



















